Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04262206 · ClinicalTrials.gov registry record · Phase 4
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
A Phase 4 study of Cardiovascular Diseases and Dementia, sponsored by Duke University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 20,000
- Enrollment target
- 20
- Study locations
NCT04262206: Recruiting Phase 4 study of Cardiovascular Diseases and Dementia, sponsored by Duke University.
NCT04262206 is a Phase 4 study of Cardiovascular Diseases and Dementia that is actively recruiting participants, run by Duke University. The registered enrollment target is 20,000 participants, below the 26,908-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (26% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04262206, a Phase 4 study of Cardiovascular Diseases and Dementia, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 20,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.
Primary Outcome
Number of patients without diagnosis of new dementia in each group (placebo vs. atorvastatin)
Conditions Studied
Interventions
- DRUG Atorvastatin 40 Mg Oral Tablet
- DRUG Placebo oral tablet
Study Locations (20)
California
- Fresno VA Medical Center - Fresno
- Long Beach VA Medical Center - Long Beach
- Cedars-Sinai Medical Center - Los Angeles
- VA Greater Los Angeles - Los Angeles
- VA Palo Alto Healthcare System - Palo Alto
- VA San Diego Medical Center - San Diego
Florida
- Bay Pines VA - Bay Pines
- Gainesville VA Medical Center - Gainesville
- University of Florida - Gainesville
- University of Florida - Jacksonville
- Miami VA Medical Center - Miami
- University of Miami - Miami
Alabama
- University of Alabama at Birmingham - Birmingham
- Birmingham VA - Birmingham
Arkansas
- Little Rock VA Medical Center - Little Rock
- University of Arkansas for Medical Sciences - Little Rock
Connecticut
- Yale University - New Haven
- VA Connecticut Healthcare System - West Haven
Arizona
- Southern Arizona VA Health Care System - Tucson - Tucson
Georgia
- Atlanta VA Medical Center - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,000 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
What NCT04262206 shows while recruiting
NCT04262206 is an interventional study that assigns participants to a tested intervention. Its 20,000 participants enrollment target places it among the larger protocols in the corpus, below the 26,908-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (26% lower).
The record links to 3 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 2 interventions - of which Atorvastatin 40 Mg Oral Tablet is the first listed.
NCT04262206 names 20 study sites across 7 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT04262206 about?
NCT04262206 is a clinical study titled "Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults". PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the b...
What is the current status of trial NCT04262206?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20,000 participants. The study started on 2020-09-01. Estimated completion is 2026-12-31.
What conditions does trial NCT04262206 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Dementia, Cognitive Impairment, Mild.
What interventions are being tested in trial NCT04262206?
The interventions under investigation include: Atorvastatin 40 Mg Oral Tablet (DRUG), Placebo oral tablet (DRUG).
Who is sponsoring clinical trial NCT04262206?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04262206 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04262206's enrollment target sits among peer trials
20,000 9th of 300 higher than 292 of 300 other Cardiovascular Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment With Aspirin After Preeclampsia: TAP Trial
RECRUITING · Phase 4
-
NSAIDs vs. Coxibs in the Presence of Aspirin
RECRUITING · Phase 4
-
Secondhand Tobacco Smoke and Cardiovascular Disease
RECRUITING · Phase 4
-
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
ACTIVE NOT RECRUITING · Phase 4
-
Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)
COMPLETED · Phase 4
-
Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00271180 · 20,000 participants
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
- NCT00830557 · 20,000 participants
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
- NCT00900471 · 20,000 participants
Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors
- NCT02735707 · 20,000 participants · Phase 3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI